Skip to content
10-Q

Quarterly Report

Intercept Pharmaceuticals, Inc.

0001558370-23-007042

← back to feed
Filed
Apr 27, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2023 · Mar 31, 2023 41.67M sh
Shares Diluted Q1 2023 · Mar 31, 2022 29.7M sh
Shares Outstanding Q1 2023 · Mar 31, 2023 41.69M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$51.6M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$20.12M
Long Term Debt Q1 2023 · Mar 31, 2023 $223.35M
Long Term Debt Q1 2023 · Dec 31, 2022 $223.1M
Short Term Debt Q1 2023 · Mar 31, 2023 $109.69M
Short Term Debt Q1 2023 · Dec 31, 2022 $109.57M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $61.4M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $50.52M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $48.32M
Stockholders Equity Q1 2023 · Mar 31, 2023 $67.19M
Stockholders Equity Q1 2023 · Dec 31, 2022 $93.08M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$371.76M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$183.96M
Current Liabilities Q1 2023 · Mar 31, 2023 $207.12M
Current Liabilities Q1 2023 · Dec 31, 2022 $230.08M
Total Liabilities Q1 2023 · Mar 31, 2023 $436.9M
Total Liabilities Q1 2023 · Dec 31, 2022 $460.63M
Current Assets Q1 2023 · Mar 31, 2023 $490.46M
Current Assets Q1 2023 · Dec 31, 2022 $540.13M
Total Assets Q1 2023 · Mar 31, 2023 $504.09M
Total Assets Q1 2023 · Dec 31, 2022 $553.71M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.77
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.58
Eps Basic Q1 2023 · Mar 31, 2023 −$0.77
Eps Basic Q1 2023 · Mar 31, 2022 −$0.58
Sga Expense Q1 2023 · Mar 31, 2023 $57.66M
Sga Expense restated Q1 2023 · Mar 31, 2022 $37.77M
Rd Expense Q1 2023 · Mar 31, 2023 $41.71M
Rd Expense restated Q1 2023 · Mar 31, 2022 $47.58M
Net Income Q1 2023 · Mar 31, 2023 −$32.14M
Net Income Q1 2023 · Mar 31, 2022 −$17.28M
Operating Income Q1 2023 · Mar 31, 2023 −$31.63M
Operating Income restated Q1 2023 · Mar 31, 2022 −$26.43M
Cost Of Revenue Q1 2023 · Mar 31, 2023 $222K
Cost Of Revenue restated Q1 2023 · Mar 31, 2022 $223K
Revenue Q1 2023 · Mar 31, 2023 $67.96M
Revenue restated Q1 2023 · Mar 31, 2022 $59.15M
Capex Q1 2023 · Mar 31, 2022 $7K